Revance Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Revance Therapeutics (NASDAQ:RVNC) reported Q3 earnings, beating estimated earnings by 38.89% with an EPS of $-0.55 versus an estimate of $-0.9. Revenue was up $27.76 million from the same period last year. Last quarter, the company missed on EPS by $0.03, which was followed by an 8.05% drop in the share price the next day.
November 08, 2023 | 9:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance Therapeutics reported better than expected Q3 earnings, which could positively impact the stock price. However, past performance shows a drop in share price following a missed EPS last quarter.
Revance Therapeutics reported a significant beat on Q3 earnings estimates, which is typically a positive signal for the stock price. However, investors should also consider the company's past performance, which shows a drop in share price following a missed EPS last quarter. This suggests potential volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100